Eltrombopag for treatment of thrombocytopenia-associated disorders

Research output: Contribution to journalArticle

Abstract

Introduction: Eltrombopag is an orally bioavailable, non-peptide thrombopoietin receptor agonist capable of stimulating platelet production through the differentiation of CD34+ hematopoietic progenitor cells into committed CD41+ megakaryocyte precursors and proliferation of megakaryocyte progenitor cells.Areas covered: This drug has been tested in several clinical trials in adult patients with chronic immune thrombocytopenia (ITP), demonstrating the ability of the drug to reduce the burden of thrombocytopenia and its associated side effects. Two multicenter trials on eltrombopag in chronic ITP of childhood have been recently completed, showing that the drug is effective also in pediatric patients. Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-C virus infection. These studies have documented that adjunct treatment with eltrombopag can help avoid either dose reductions or withdrawal of pegylated interferon due to development of thrombocytopenia. Eltrombopag has shown efficacy also in patients with acquired severe aplastic anemia and myelodysplastic syndromes.Expert opinion: Eltrombopag plays an important therapeutic role in many different conditions characterized by persistent thrombocytopenia. A more comprehensive definition of both long-term safety and benefits deriving from the use of eltrombopag will be obtained through prolonged observation of patients already enrolled in the different studies conducted so far and from future prospective controlled trials.

Original languageEnglish
Pages (from-to)2243-2256
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number14
DOIs
Publication statusPublished - Sep 22 2015

Fingerprint

Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Therapeutics
Thrombopoietin Receptors
Megakaryocyte Progenitor Cells
Pharmaceutical Preparations
Megakaryocytes
Aplastic Anemia
Myelodysplastic Syndromes
Expert Testimony
Virus Diseases
Hematopoietic Stem Cells
eltrombopag
Hepacivirus
Interferons
Multicenter Studies
Blood Platelets
Observation
Clinical Trials
Pediatrics

Keywords

  • bleeding disorders
  • eltrombopag
  • immune thrombocytopenia
  • severe aplastic anemia
  • thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Eltrombopag for treatment of thrombocytopenia-associated disorders. / Merli, Pietro; Strocchio, Luisa; Vinti, Luciana; Palumbo, Giuseppe; Locatelli, Franco.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 14, 22.09.2015, p. 2243-2256.

Research output: Contribution to journalArticle

@article{d3c606c7d41d440aa95f9509b530d510,
title = "Eltrombopag for treatment of thrombocytopenia-associated disorders",
abstract = "Introduction: Eltrombopag is an orally bioavailable, non-peptide thrombopoietin receptor agonist capable of stimulating platelet production through the differentiation of CD34+ hematopoietic progenitor cells into committed CD41+ megakaryocyte precursors and proliferation of megakaryocyte progenitor cells.Areas covered: This drug has been tested in several clinical trials in adult patients with chronic immune thrombocytopenia (ITP), demonstrating the ability of the drug to reduce the burden of thrombocytopenia and its associated side effects. Two multicenter trials on eltrombopag in chronic ITP of childhood have been recently completed, showing that the drug is effective also in pediatric patients. Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-C virus infection. These studies have documented that adjunct treatment with eltrombopag can help avoid either dose reductions or withdrawal of pegylated interferon due to development of thrombocytopenia. Eltrombopag has shown efficacy also in patients with acquired severe aplastic anemia and myelodysplastic syndromes.Expert opinion: Eltrombopag plays an important therapeutic role in many different conditions characterized by persistent thrombocytopenia. A more comprehensive definition of both long-term safety and benefits deriving from the use of eltrombopag will be obtained through prolonged observation of patients already enrolled in the different studies conducted so far and from future prospective controlled trials.",
keywords = "bleeding disorders, eltrombopag, immune thrombocytopenia, severe aplastic anemia, thrombocytopenia",
author = "Pietro Merli and Luisa Strocchio and Luciana Vinti and Giuseppe Palumbo and Franco Locatelli",
year = "2015",
month = "9",
day = "22",
doi = "10.1517/14656566.2015.1085512",
language = "English",
volume = "16",
pages = "2243--2256",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "14",

}

TY - JOUR

T1 - Eltrombopag for treatment of thrombocytopenia-associated disorders

AU - Merli, Pietro

AU - Strocchio, Luisa

AU - Vinti, Luciana

AU - Palumbo, Giuseppe

AU - Locatelli, Franco

PY - 2015/9/22

Y1 - 2015/9/22

N2 - Introduction: Eltrombopag is an orally bioavailable, non-peptide thrombopoietin receptor agonist capable of stimulating platelet production through the differentiation of CD34+ hematopoietic progenitor cells into committed CD41+ megakaryocyte precursors and proliferation of megakaryocyte progenitor cells.Areas covered: This drug has been tested in several clinical trials in adult patients with chronic immune thrombocytopenia (ITP), demonstrating the ability of the drug to reduce the burden of thrombocytopenia and its associated side effects. Two multicenter trials on eltrombopag in chronic ITP of childhood have been recently completed, showing that the drug is effective also in pediatric patients. Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-C virus infection. These studies have documented that adjunct treatment with eltrombopag can help avoid either dose reductions or withdrawal of pegylated interferon due to development of thrombocytopenia. Eltrombopag has shown efficacy also in patients with acquired severe aplastic anemia and myelodysplastic syndromes.Expert opinion: Eltrombopag plays an important therapeutic role in many different conditions characterized by persistent thrombocytopenia. A more comprehensive definition of both long-term safety and benefits deriving from the use of eltrombopag will be obtained through prolonged observation of patients already enrolled in the different studies conducted so far and from future prospective controlled trials.

AB - Introduction: Eltrombopag is an orally bioavailable, non-peptide thrombopoietin receptor agonist capable of stimulating platelet production through the differentiation of CD34+ hematopoietic progenitor cells into committed CD41+ megakaryocyte precursors and proliferation of megakaryocyte progenitor cells.Areas covered: This drug has been tested in several clinical trials in adult patients with chronic immune thrombocytopenia (ITP), demonstrating the ability of the drug to reduce the burden of thrombocytopenia and its associated side effects. Two multicenter trials on eltrombopag in chronic ITP of childhood have been recently completed, showing that the drug is effective also in pediatric patients. Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-C virus infection. These studies have documented that adjunct treatment with eltrombopag can help avoid either dose reductions or withdrawal of pegylated interferon due to development of thrombocytopenia. Eltrombopag has shown efficacy also in patients with acquired severe aplastic anemia and myelodysplastic syndromes.Expert opinion: Eltrombopag plays an important therapeutic role in many different conditions characterized by persistent thrombocytopenia. A more comprehensive definition of both long-term safety and benefits deriving from the use of eltrombopag will be obtained through prolonged observation of patients already enrolled in the different studies conducted so far and from future prospective controlled trials.

KW - bleeding disorders

KW - eltrombopag

KW - immune thrombocytopenia

KW - severe aplastic anemia

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84941362407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941362407&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1085512

DO - 10.1517/14656566.2015.1085512

M3 - Article

C2 - 26364898

AN - SCOPUS:84941362407

VL - 16

SP - 2243

EP - 2256

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 14

ER -